Get the Stockscreener App
100.40
0.07%
0.07
Inhibrx Biosciences Inc stock is traded at $100.40, with a volume of 285.51K.
It is up +0.07% in the last 24 hours and down -4.33% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$100.33
Open:
$102.38
24h Volume:
285.51K
Relative Volume:
0.91
Market Cap:
$1.48B
Revenue:
$1.30M
Net Income/Loss:
$-130.19M
P/E Ratio:
-11.97
EPS:
-8.3898
Net Cash Flow:
$-131.94M
1W Performance:
-4.13%
1M Performance:
-4.33%
6M Performance:
+59.06%
1Y Performance:
+238.05%
1-Day Range:
$99.53
$104.49
1-Week Range:
$98.56
$117.14
52-Week Range:
$28.16
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
100.40 | 1.48B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history - Yahoo Finance UK
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? - Insider Monkey
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September - Investing.com India
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com UK
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences stock gains on insider buying and trial progress - AD HOC NEWS
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
Inhibrx Biosciences stock gains institutional support as Bank of America invests - AD HOC NEWS
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Insider Stock Purchases: September 18, 2026 - Moomoo
Inhibrx Biosciences (NASDAQ: INBX) Director Kayyem Jon Faiz Acquires 5,000 Shares at $100 Each - Kalkine Media
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? - The Motley Fool
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Inhibrx Biosciences gains FDA acceptance for oz... - Pluang
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106 - Seeking Alpha
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - Benzinga
Inhibrx reports INBRX-106 Phase 2 cancer trial results - grafa.com
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial - Seeking Alpha
Inhibrx Biosciences Announces Primary Endpoint Results from Phase 2 HexAgon Study Of INBRX-106 In Combination With Pembrolizumab In HNSCC - marketscreener.com
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):